PDCD1 and melanoma: Taken together, these results are consistent with LAG-3 playing a key role in PD-1 and/or CTLA-4 blockade resistance, and provides additional rationale for targeting LAG-3 (in combination with PD-1) as a strategy to overcome ICI resistance in melanoma and possibly other solid tumor types.